Sofinnova Ventures Inc Buys NextCure Inc, PTC Therapeutics Inc, Acceleron Pharma Inc, Sells AstraZeneca PLC, Coherus BioSciences Inc, Alnylam Pharmaceuticals Inc

• New Purchases: NXTC, PTCT, XLRN, VRTX, BMY, ACAD, ZYME, ABBV, CALA, ITCI, BCRX, ACOR, FTSV, AUTL,
• Added Positions: ASND, TGTX, HRTX, BMRN, HALO, RETA, NVO, NBIX, MOR, DERM, AKBA, INCY, KDMN, OSMT, OTIC, CLVS, FOMX, XBIT, MGNX, SNDX, ADVM,
• Reduced Positions: CHRS, ALNY, AGN, ARQL, KALA,
• Sold Out: AZN, ANAB, XNCR, BHVN, BPMC, SVRA, ICPT, DCPH, INSM, FATE, GWPH, FGEN, PTLA,

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolioportfolio

1. Ascendis Pharma A/S (ASND) - 1,099,824 shares, 12.85% of the total portfolio. Shares added by 10.14%
2. Amarin Corp PLC (AMRN) - 5,208,305 shares, 10.24% of the total portfolio.
3. Natera Inc (NTRA) - 3,100,560 shares, 8.67% of the total portfolio.
4. Principia Biopharma Inc (PRNB) - 2,038,208 shares, 6.86% of the total portfolio.
5. ObsEva SA (OBSV) - 4,749,623 shares, 5.45% of the total portfolio.

Sofinnova Ventures Inc initiated holding in NextCure Inc. The purchase prices were between $14.16 and $20.64, with an estimated average price of $17.39. The stock is now traded at around $26.71. The impact to a portfolio due to this purchase was 3.83%. The holding were 2,521,856 shares as of .

Sofinnova Ventures Inc initiated holding in PTC Therapeutics Inc. The purchase prices were between $35.42 and $45, with an estimated average price of $39.44. The stock is now traded at around $46.40. The impact to a portfolio due to this purchase was 1.68%. The holding were 368,903 shares as of .

Sofinnova Ventures Inc initiated holding in Acceleron Pharma Inc. The purchase prices were between $37.52 and $46.93, with an estimated average price of $41.39. The stock is now traded at around $45.99. The impact to a portfolio due to this purchase was 1%. The holding were 241,043 shares as of .

Sofinnova Ventures Inc initiated holding in Vertex Pharmaceuticals Inc. The purchase prices were between $164.61 and $190.37, with an estimated average price of $174.67. The stock is now traded at around $183.91. The impact to a portfolio due to this purchase was 0.94%. The holding were 50,301 shares as of .

Sofinnova Ventures Inc initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $44.62 and $49.34, with an estimated average price of $46.57. The stock is now traded at around $46.49. The impact to a portfolio due to this purchase was 0.8%. The holding were 173,849 shares as of .

Sofinnova Ventures Inc initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $23.32 and $28.12, with an estimated average price of $25.52. The stock is now traded at around $29.45. The impact to a portfolio due to this purchase was 0.42%. The holding were 155,576 shares as of .

Sofinnova Ventures Inc added to a holding in TG Therapeutics Inc by 258.54%. The purchase prices were between $6.27 and $8.65, with an estimated average price of $7.56. The stock is now traded at around $7.19. The impact to a portfolio due to this purchase was 0.8%. The holding were 1,261,384 shares as of .

Sofinnova Ventures Inc added to a holding in Heron Therapeutics Inc by 164.15%. The purchase prices were between $16.93 and $26.22, with an estimated average price of $20. The stock is now traded at around $18.17. The impact to a portfolio due to this purchase was 0.72%. The holding were 617,185 shares as of .

Sofinnova Ventures Inc added to a holding in Biomarin Pharmaceutical Inc by 359.05%. The purchase prices were between $80.35 and $93.9, with an estimated average price of $85.56. The stock is now traded at around $73.46. The impact to a portfolio due to this purchase was 0.58%. The holding were 84,896 shares as of .

Sofinnova Ventures Inc added to a holding in Halozyme Therapeutics Inc by 71.98%. The purchase prices were between $14.75 and $17.26, with an estimated average price of $16.12. The stock is now traded at around $16.22. The impact to a portfolio due to this purchase was 0.5%. The holding were 690,199 shares as of .

Sofinnova Ventures Inc added to a holding in Reata Pharmaceuticals Inc by 77.66%. The purchase prices were between $77.72 and $94.35, with an estimated average price of $86.24. The stock is now traded at around $77.71. The impact to a portfolio due to this purchase was 0.49%. The holding were 115,536 shares as of .

Sofinnova Ventures Inc added to a holding in Novo Nordisk A/S by 30.66%. The purchase prices were between $46.79 and $52.47, with an estimated average price of $49.39. The stock is now traded at around $51.85. The impact to a portfolio due to this purchase was 0.39%. The holding were 323,697 shares as of .

Sofinnova Ventures Inc sold out a holding in AstraZeneca PLC. The sale prices were between $37.28 and $41.68, with an estimated average price of $39.2.

Sofinnova Ventures Inc sold out a holding in AnaptysBio Inc. The sale prices were between $53.76 and $81.12, with an estimated average price of $72.07.

Sofinnova Ventures Inc sold out a holding in Xencor Inc. The sale prices were between $29.6 and $40.93, with an estimated average price of $32.83.

Sofinnova Ventures Inc sold out a holding in Biohaven Pharmaceutical Holding Co Ltd. The sale prices were between $39.79 and $67.01, with an estimated average price of $56.51.

Sofinnova Ventures Inc sold out a holding in Blueprint Medicines Corp. The sale prices were between $73.54 and $97.8, with an estimated average price of $82.43.

Sofinnova Ventures Inc sold out a holding in Savara Inc. The sale prices were between $2.37 and $11.7, with an estimated average price of $8.93.